Enabling new discoveries with cutting edge technologies
In 2018, the United Kingdom completed its initiative of sequencing 100,000 genomes with the hopes that their findings would lead to better, earlier diagnosis and personalized healthcare for cancer, rare diseases, and infectious diseases. The closing of this study is reflective of how far the sequencing industry has come since the Human Genome Project (HGP) was declared complete in 2003. The development of new genomic and next generation sequencing (NGS) technologies has not only led to advancements in biopharma but in many different markets such as agriculture, consumer genomics, population-scale genomics, and synthetic biology. Companies like Thermo Fisher Scientific, Inc. are on the forefront of leading the market for the creation of new technologies, products, and services to support the growing field of genomics and next generation sequencing.